Investor Resources
Crinetics Reviews Phase 1 CRN04777 Multiple-Ascending Dose Data
Mar 30, 2022 at 4:30 PM EDT
Crinetics management will discuss the positive top-line results from the multiple-ascending dose cohorts of a first-in-human Phase 1 clinical study of CRN04777 that were reported today.